Navigation Links
AMRESCO Invests in New Powder Manufacturing Facility to Support Growth in Life Science Business
Date:6/25/2013

Cleveland, Ohio (PRWEB) June 25, 2013

AMRESCO, LLC, a VWR company and a Life Science leader in the supply and contract manufacturing of high purity biochemicals, reagents and research products, announced that it has invested in a new powder manufacturing facility to support growing global business to Diagnostic, Molecular Biology and Biopharmaceutical companies. AMRESCO’s investment is part of its ongoing strategy to help increase its customers’ operational efficiencies and profitability. Its breadth of services and manufacturing capabilities offers a strong value platform and strengthens its mission to support customers and their products.

AMRESCO’s new facility increases its powder manufacturing capacity by 150%, expanding capabilities for particle size reduction, homogenous powder blending, precision powder dosing for pouching, and tablet production. This expanded and enhanced production helps to support growing product lines such as buffer blends and dehydrated media blends.

Over 35% of AMRESCO’s customers require specific formulation needs. The additional powder manufacturing capabilities and capacity allow AMRESCO to manufacture, dose and package a wider variety of powder products with varying volumes, as well as offer customers the sensitivity and most importantly, the throughput that their product requires.

Jim Taliak, VP of Global Sales at AMRESCO states, “Our customers are challenged with speed to market, operational constraints, and lack of capital or expertise. They are focusing on activities and efforts that don’t always align with their best strategic interest. Together, we look at where they need to be, then employ our skill and capabilities to assure their success.”

ABOUT AMRESCO
For nearly four decades, AMRESCO has been serving life sciences research and commercial production customers worldwide, bringing them high purity biochemicals, custom manufacturing solutions, innovative research products and strategic services including Product Design, Transfer and Engineering. AMRESCO products and services support the growing In Vitro Diagnostic, Molecular Diagnostic, Life Science Tool Providers and Biopharm market segments.

For further information, contact: Deborah Neilly, Marketing and Communications
V: 440.914.3311 E: dneilly(at)amresco-inc(dot)com

Read the full story at http://www.prweb.com/releases/2013/6/prweb10854471.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. AMRESCO’s New Fluorescent DNA Quantitation Kit Uses a Highly Specific DNA-binding Dye that Allows Accurate Quantitation Even in Crude Extracts
2. AMRESCO’s New VisiGlo™ Prime and VisiGlo™ Select HRP Chemiluminescent Substrate Kits Offer Long-lasting, High Sensitivity Detection
3. AMRESCO Offers New Prism Protein Marker With Vibrant Colors For Easy Band Identification
4. DuPont, American Farm Bureau Foundation Invests $250,000 in My American Farm Web Education Program
5. UPMC Invests in Intelligent Infrastructure with IBM to Support Vision of Personalized Medicine
6. JumpStart Invests $250,000 in Milo Biotechnology
7. AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited
8. SAFC Expands Irvine Facility to Add Dry Powder Media Manufacturing Capabilities
9. TM&S Opens Office Dedicated to Powder Metal, Metal Injection Molding and Liquid Metal
10. Rigaku Publishes New Application for Cement Analysis by the Pressed Powder Method on the ZSX Primus III+ According to ASTM C114-11
11. Rigaku Publishes New Application Note: Cement Raw Meal Analysis by Pressed Powder Method on the ZSX Primus III+
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... -- IBM (NYSE: IBM ) scientists have developed ... molecules with the potential to efficiently reveal biomarkers ... complements the IBM Research,s "lab-on-a-chip" nanoDLD technology ... which may also contain biomarkers for disease detection. ... diamond shaped micropillars 1 to pre-stretch DNA ...
(Date:5/12/2017)... , May 12, 2017  Eli Lilly and ... that galcanezumab, an investigational treatment for the prevention ... endpoint in three Phase 3 studies (EVOLVE-1, EVOLVE-2 ... number of monthly migraine headache days compared to ... "The robust results from these three studies bring ...
(Date:5/11/2017)... ... 2017 , ... Quorum Review IRB , the first name in streamlined, ... SMART IRB , a platform designed to simplify the IRB review process for ... to multi-site research and serve as a roadmap for institutions to execute the ...
(Date:5/11/2017)... Angeles, California (PRWEB) , ... May 11, 2017 , ... ... at our feet. , Multiple Sclerosis (MS) is a neurological disorder that can ... the immune system's attack of one's own brain cells. MS arises from a genetic ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
Breaking Biology News(10 mins):